Cingulate Inc
CINGW0.060USD
+0.005+9.69%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Cingulate Inc Company
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Cingulate Inc Info
Ticker SymbolCINGW
Company nameCingulate Inc
IPO dateOct 07, 2021
CEOMs. Jennifer L. Callahan
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address1901 W. 47Th Place
CityKANSAS CITY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code66205
Phone19139422300
Websitehttps://www.cingulate.com/
Ticker SymbolCINGW
IPO dateOct 07, 2021
CEOMs. Jennifer L. Callahan
Company Executives of Cingulate Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
11
227.30K
0.00%
-784.58K
2025Q3
12
227.30K
0.00%
+13.50K
2025Q2
12
213.80K
0.00%
-25.05K
2025Q1
12
238.84K
0.00%
-824.25K
2024Q4
11
230.16K
0.00%
-296.57K
2024Q3
11
526.73K
0.00%
-509.74K
2024Q2
11
1.54M
0.00%
+20.01K
2024Q1
10
1.52M
0.00%
-577.42K
2023Q4
10
2.04M
0.00%
-3.83K
2023Q3
9
2.05M
0.00%
-52.84K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hudson Bay Capital Management LP
210.80K
0%
--
--
Sep 30, 2025
Citadel Advisors LLC
--
0%
-12.58K
-100.00%
Jun 30, 2025
GoalVest Advisory, LLC
3.00K
0%
--
--
Sep 30, 2025
Armistice Capital LLC
--
0%
-1.71K
-100.00%
Mar 31, 2025
Altium Capital Management LP
--
0%
-270.00K
-100.00%
Dec 31, 2024
Sabby Management, LLC
--
0%
-458.52K
-100.00%
Sep 30, 2024
Warberg Asset Management LLC
--
0%
-43.16K
-100.00%
Sep 30, 2024
Virtu Americas LLC
10.60K
0%
+10.60K
--
Sep 30, 2025
BofA Global Research (US)
--
0%
-100.00
-100.00%
Sep 30, 2024
UBS Financial Services, Inc.
2.90K
0%
+2.90K
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Cingulate Inc?
The top five shareholders of Cingulate Inc are:
Hudson Bay Capital Management LP holds 210.80K shares, accounting for 0.00% of the total shares.
Citadel Advisors LLC holds 0.00 shares, accounting for 0.00% of the total shares.
GoalVest Advisory, LLC holds 3.00K shares, accounting for 0.00% of the total shares.
Armistice Capital LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Altium Capital Management LP holds 0.00 shares, accounting for 0.00% of the total shares.
Hudson Bay Capital Management LP holds 210.80K shares, accounting for 0.00% of the total shares.
Citadel Advisors LLC holds 0.00 shares, accounting for 0.00% of the total shares.
GoalVest Advisory, LLC holds 3.00K shares, accounting for 0.00% of the total shares.
Armistice Capital LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Altium Capital Management LP holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Cingulate Inc?
The top three shareholder types of Cingulate Inc are:
Other
Other
How many institutions hold shares of Cingulate Inc (CINGW)?
As of 2025Q4, 11 institutions hold shares of Cingulate Inc, with a combined market value of approximately 227.30K, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Cingulate Inc?
In --, the -- business generated the highest revenue for Cingulate Inc, amounting to -- and accounting for --% of total revenue.
